0ND5 Stock Overview A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details
Rewards Risk Analysis No risks detected for 0ND5 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
H. Lundbeck A/S Competitors Price History & Performance
Summary of share price highs, lows and changes for H. Lundbeck Historical stock prices Current Share Price DKK 40.98 52 Week High DKK 49.38 52 Week Low DKK 31.60 Beta 0.19 1 Month Change -6.60% 3 Month Change -8.93% 1 Year Change 26.91% 3 Year Change n/a 5 Year Change n/a Change since IPO 22.35%
Recent News & Updates
H. Lundbeck A/S Announces Positive Results from the Resolve Trial Dec 03
H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy Nov 27
Third quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.68 in 3Q 2023) Nov 14
H. Lundbeck A/S Raises Earnings Guidance for the Year 2024 Nov 14
H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention Nov 01 H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion. Oct 15
See more updates
H. Lundbeck A/S Announces Positive Results from the Resolve Trial Dec 03
H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy Nov 27
Third quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.68 in 3Q 2023) Nov 14
H. Lundbeck A/S Raises Earnings Guidance for the Year 2024 Nov 14
H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention Nov 01 H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion. Oct 15
H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion. Oct 14
H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease Oct 03 H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders Sep 27
Second quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.60 in 2Q 2023) Aug 21 Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder Jun 25
H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial Jun 20
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia Jun 05
H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025 May 17
First quarter 2024 earnings released: EPS: kr.1.01 (vs kr.0.89 in 1Q 2023) May 16 H. Lundbeck A/S Provides Earnings Guidance for the Year 2024 May 16
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024 May 14
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD Apr 10 Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia Mar 28
H. Lundbeck A/S Announces Management Appointments H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage Mar 15
Upcoming dividend of kr.0.70 per share Mar 14 H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023
Key Executive recently bought kr.751k worth of stock Feb 20
Dividend increased to kr.0.70 Feb 11
Full year 2023 earnings released: EPS: kr.2.31 (vs kr.1.93 in FY 2022) Feb 09
Less than half of directors are independent Feb 09
H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024 Feb 05 Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial Jan 31
H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024
H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024 Nov 08
H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea Sep 14 Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults Sep 08
H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart Aug 19
H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024 Aug 18
H. Lundbeck A/S Raises Earnings Guidance for the Year 2023 Aug 17
H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole Jun 28
European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole Jun 18
H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti Jun 16
H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index Jun 11
H. Lundbeck A/S Common Stock to Be Deleted from OTC Equity Jun 10
First quarter 2022 earnings released: EPS: kr.2.07 (vs kr.3.13 in 1Q 2021) May 13
H. Lundbeck A/S Provides Earnings Guidance for the Year 2022 May 12
Less than half of directors are independent Apr 27
H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the Role of Vortioxetine Apr 11 H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management
Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI Apr 04
Less than half of directors are independent Mar 31
Upcoming dividend of kr.2.00 per share Mar 17
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 10 H. Lundbeck A/S Proposes Dividend for the Year 2021
EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine in Adults Jan 25
Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17 Jan 07
Third quarter 2021 earnings released: EPS kr.1.62 (vs kr.2.38 in 3Q 2020) Nov 11
Second quarter 2021 earnings released: EPS kr.1.90 (vs kr.2.93 in 2Q 2020) Aug 22
First quarter 2021 earnings released: EPS kr.3.13 (vs kr.0.76 in 1Q 2020) May 13
H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021 May 12
H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder May 04 Shareholder Returns 0ND5 GB Pharmaceuticals GB Market 7D -3.0% -1.5% -1.5% 1Y 26.9% -2.8% 3.5%
See full shareholder returns
Return vs Market: 0ND5 exceeded the UK Market which returned 4.6% over the past year.
Price Volatility Is 0ND5's price volatile compared to industry and market? 0ND5 volatility 0ND5 Average Weekly Movement 3.3% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0ND5 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0ND5's weekly volatility (3%) has been stable over the past year.
About the Company H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.
Show more H. Lundbeck A/S Fundamentals Summary How do H. Lundbeck's earnings and revenue compare to its market cap? 0ND5 fundamental statistics Market cap DKK 39.25b Earnings (TTM ) DKK 2.69b Revenue (TTM ) DKK 21.44b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0ND5 income statement (TTM ) Revenue DKK 21.44b Cost of Revenue DKK 4.38b Gross Profit DKK 17.06b Other Expenses DKK 14.37b Earnings DKK 2.69b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
Earnings per share (EPS) 2.71 Gross Margin 79.56% Net Profit Margin 12.53% Debt/Equity Ratio 15.6%
How did 0ND5 perform over the long term?
See historical performance and comparison Dividends
1.7% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 06:19 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources H. Lundbeck A/S is covered by 39 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Ankersen ABG Sundal Collier Kamla Singh AlphaValue Charles Pitman Barclays
Show 36 more analysts 
